Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 Infection

When to Initiation Antitumor Therapy for Tumor Patients With COVID19 Infection

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06006845

Enrollment

100

Registered

2023-08-23

Start date

2022-12-01

Completion date

2024-08-31

Last updated

2023-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Tumor

Keywords

Tumor patients, COVID-19, antitumor therapy

Brief summary

The goal of this observational study is to study the safety of initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19. The main questions aims to answer are: * Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases adverse events related to antitumor therapy. * Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases risk of re-infection of COVID-19. * How initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 affects QoL of tumor patients Participants will be asked to answer the question about: * the severity and duration of COVID-19 symptoms * the date of diagnosis of COVID-19 * the date of negative nucleic acid test * the QoL of life before infection with COVID-19, during infection of COVID-19, after nucleic acid test negativity and receiving antitumor therapy

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Tumor patients diagnosed with COVID-19 infection at our center from December 1, 2022 to May 31. * COVID-19 was confirmed by antigen testing or nucleic acid testing. * Tumor was confirmed by pathology. * Patients received systemic antitumor therapy after infected with COVID-19.

Exclusion criteria

* COVID-19 was not confirmed by antigen testing or nucleic acid testing * Tumor was not confirmed by pathology * Patients did not receive systemic antitumor therapy * Patients died before receiving systemic antitumor therapy

Design outcomes

Primary

Measure	Time frame	Description
Incidence of adverse events after antitumor therapy	28 days after antitumor therapy	Incidence of adverse events after antitumor therapy, including hematologic toxicity,gastrointestinal adverse event, hepatobiliary adverse events, etc.
Re-infection of COVID-19	28 days after antitumor therapy	Antigen testing or nucleic acid testing positive for COVID-19

Secondary

Measure	Time frame	Description
Clinical manifestations of COVID-19 in tumor patients	Until nucleic acid testing turn negative	Symptoms and lab abnormality of COVID-19 in tumor patients

Countries

China

Contacts

Primary ContactXiaofen Pan, MD

panxf8@mail.sysu.edu.cn+8618124671750

Backup ContactBo Wang, MD

wangb68377@sina.com0755-81206796

Outcome results